UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).

UCLA awarded $1.72M NIH grant to train brain cancer scientists

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a $1.72 million grant from NIH to support the Neuro-Oncology Translational Research Training Program, an initiative designed to train the next generation of brain tumor scientists and physician-scientists.

February 07, 2025

Vol.51 No.05

Clinical Roundup

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Urine test for prostate cancer could be used at home, study finds

Researchers at Vanderbilt and the University of Michigan have shown that an at-home urine test for prostate cancer screening is highly accurate.

February 07, 2025

Vol.51 No.05

Drugs & Targets

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

FDA granted orphan drug designation to MB-105, March Biosciences’s first-in-class CD5-targeted CAR T-cell therapy, for the treatment of relapsed/refractory CD5-positive T-cell lymphoma.

February 07, 2025

Vol.51 No.05

Less taxing therapies taking center stage

Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair.

January 31, 2025

Vol.51 No.04

By City of Hope

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

YOU MAY BE INTERESTED IN

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

UCLA awarded $1.72M NIH grant to train brain cancer scientists

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

Urine test for prostate cancer could be used at home, study finds

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

Less taxing therapies taking center stage

Renew today!

Subscriber content

Never miss an issue!

Login